Navigation Links
Experimental Drug Might Help Fight Alzheimer's After All
Date:7/20/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, July 20 (HealthDay News)-- An experimental drug for treating Alzheimer's disease that previously showed troubling side effects may actually be safe in the long run, researchers report.

The keys to the safety of the drug, bapineuzumab, may be lowering the dose and not giving it to patients with ApoE4, a gene mutation linked to Alzheimer's, according to two studies scheduled for presentation Wednesday at the Alzheimer's Association International Conference on Alzheimer's Disease in Paris.

"The data from the open-label trial are encouraging. Patients were able to tolerate bapineuzumab for two to four additional years without the emergence of any new safety concerns," said Dr. Stephen Salloway, author of one of the studies. "This is important because we are conceptualizing this drug as a long-term treatment for Alzheimer's disease."

Encouraging does not translate into certainty, however, another expert pointed out.

"I think it is too early to tell from the data from this small Phase 2 safety trial," said Ian Murray, an assistant professor of neuroscience and experimental therapeutics at Texas A&M Health Science Center College of Medicine in College Station. "We will have to wait for larger trials to comment on this as a potential therapy."

The studies were funded by Pfizer Inc. and Janssen Alzheimer Immunotherapy.

Although bapineuzumab has shown promise in certain Alzheimer's patients, other research found that patients taking a higher dose of the drug had an increased risk of brain inflammation from water retention. This resulted in headache, memory loss, hallucinations, reduced coordination or other symptoms. But no problems were seen with lower doses.

Bapineuzumab is a humanized monoclonal antibody, which binds to and might be able to eliminate beta amyloid peptide in the brains of people with Alzheimer's. Most experts believe that the b
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
2. Experimental Vaccine Seems to Cure Prostate Cancer in Mice
3. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
4. Ex-Dallas Maverick survives rare form of leukemia thanks to experimental drug treatment
5. Experimental treatment offers relief from painful prostate condition
6. Christos Mantzoros honored by Federation of the American Societies for Experimental Biology
7. Experimental Test May Warn of Premature Births
8. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
9. Experimental Weight-Loss Drug Seems to Work: Study
10. Experimental drug achieves unprecedented weight loss
11. Science at a glance: Symposia, research and special events at Experimental Biology 2011
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Might Help Fight Alzheimer's After All
(Date:1/22/2015)... Bradley, Illinois (PRWEB) January 22, 2015 Deer ... -- will host a Valentine’s Day Happy Hour from 3 p.m. ... located at 12500 Regency Parkway in Huntley, Illinois, serves adults with ... Happy Hour event will include Valentine's Day treats, games and sweetheart-themed ...
(Date:1/22/2015)... Va. (PRWEB) January 22, 2015 Liberty University ... Counseling (M.A.) program from the Council for Accreditation ... program, part of Liberty’s Center for Counseling & Family ... founding dean of the university’s new School of Behavioral Sciences. ...
(Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... Group, Inc. will provide substantial ... revenues for the company, ... American Health Resorts, Inc. (Pink Sheets:,CAHR) of Beverly Hills, California, today ... corporate note deal valued at,approximately $8 million., With Momentum Medical ...
... ... Total Debt Reduced, BIRMINGHAM, Ala., Feb. 25 HealthSouth,Corporation (NYSE: ... the fourth quarter ended December 31, 2007. Compared to the,fourth quarter ... by 4.6% and discharges increased by,0.9%., "We are pleased with ...
... 25 Lung Cancer Alliance,(LCA) cautioned today that recently ... more people each year than all the other,major cancers ... of government statistics,entitled Cancer Facts and Figures for 2008, ... been made against cancer over the,past 15 years.", ...
... ... - ANNUAL REVENUES INCREASED 34.5% ... FFO PER SHARE UP 7.8%, NEWPORT BEACH, Calif., Feb. 25 Nationwide,Health Properties, Inc. ... investment activity., "We ended 2007 on a strong note with fourth quarter revenues up ...
... COLUMBUS, Ohio Scientists have identified the role of ... in resisting certain classes of antibiotics. , The finding ... could target bacterial resistance at its cellular source. Before ... of the activities at play in the conflict between ...
... Sunrise Senior Living,Inc. (NYSE: SRZ ) ... on March 3, 2008. Management will not be ... and explanations of,variances will be included in the ... be released before markets open., About Sunrise ...
Cached Medicine News:Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 2Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 3Health News:Vital Health Technologies, Inc. / Caribbean American Health Resorts Inc. Acquires Momentum Medical Group, Inc. 4Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 2Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 3Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 4Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 5Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 6Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 7Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 8Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 9Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 10Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 11Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 12Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 13Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 14Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 15Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 16Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 17Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 18Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 19Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 20Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 21Health News:HealthSouth Reports Results for Fourth Quarter Ended December 31, 2007 22Health News:'Enormous Progress' in Reducing Cancer Does Not Include Lung Cancer 2Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 2Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 3Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 4Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 5Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 6Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 7Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 8Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 9Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 10Health News:NHP Reports Fourth Quarter and Full Year 2007 Earnings 11
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 11, 2011 MonoSol Rx, a specialty pharmaceutical ... platform, in collaboration with APR Applied Pharma Research ... FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is ... Company made the strategic decision to reacquire the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Product Profiles: Systemic ... and hope to market ... order this report: ...
Cached Medicine Technology:MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 2MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 3
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... the Finntip Wide is designed especially for ... genomic DNA. This tip eliminates the mechanical ... excellent for use with extremely viscous liquids. ... of the orifice is 1.1 mm or ...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels...
Medicine Products: